Recent

% | $
Quotes you view appear here for quick access.

Quidel Corp. Message Board

qdelfan 3 posts  |  Last Activity: Jul 11, 2016 2:19 AM Member since: Sep 30, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    mrna technology

    by qdelfan Jul 6, 2016 10:23 AM
    qdelfan qdelfan Jul 11, 2016 2:19 AM Flag

    Thanks Third, for your assessment of these new platforms, and their potential challenges to overcome to be successful. Of course 15 years ago. there was lots of doubt about the likelihood of small molecule CFTR potentiators or correctors as well. If the Vertex HBE in vitro assays show successful production of CFTR using gene editing or mRNA insertion techniques in treated CF HBE cells, I would hope that nuclease degradation would not be too much different in the human body. I look forward to hearing about these test results in the coming years to see if these technologies can possibly deliver on their promise.

  • Reply to

    mrna technology

    by qdelfan Jul 6, 2016 10:23 AM
    qdelfan qdelfan Jul 6, 2016 5:35 PM Flag

    Third what are your impressions of the prospects of the mRNA platform from Moderna Therapeutics to treat CF versus gene editing technology licensed from CRSPR?

  • qdelfan by qdelfan Jul 6, 2016 10:23 AM Flag

    David Altshuler, VRTX CSO, announced VRTX is partnering with yet another company with a novel cutting edge approach to treating CF. So now VRTX has commercial rights to Pharion's EnAc drug, CRSPR's technology, and Moderna's mRNA platform to test it's ability to improve CFTR function. Judging from VRTX stock price reaction, the analysts apparently like the news.

QDEL
21.91-0.20(-0.90%)Sep 28 4:00 PMEDT